Hepatoid adenocarcinoma of the colon: What should we target?

Alessandro Cappetta, Francesca Bergamo, Claudia Mescoli, Sara Lonardi, Massimo Rugge, Vittorina Zagonel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hepatoid adenocarcinoma is a rare extra hepatic neoplasm that displays morphological and phenotypic features similar to those of hepatocellular carcinoma. We report a case of a 75-year-old woman, presenting with abdominal pain and complaints of weakness and lost of appetite, who was found to have a mass on her right colon. She underwent right hemicolectomy for a pT3N2M0, stage IIIC colon cancer. The tumor phenotype and immunophenotype, as documented by alpha-fetoprotein immunoreaction positivity, were consistent with adenocarcinoma of hepatoid origin. The patient received FOLFOX-4 regimen as adjuvant treatment, relapsed after six cycles, then was switched to FOLFIRI regimen plus Bevacizumab and progressed after only four cycles. She died 1 month later, eight months after the diagnosis. The lack of any clinical benefit despite an aggressive and multimodal therapeutic strategy, raises a question about what should be targeted when we face this rare disease associated with a very poor prognosis.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalPathology and Oncology Research
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Colon
Adenocarcinoma
alpha-Fetoproteins
Appetite
Liver Neoplasms
Rare Diseases
Colonic Neoplasms
Abdominal Pain
Hepatocellular Carcinoma
Phenotype
Therapeutics
Neoplasms
Bevacizumab

Keywords

  • Alpha-fetoprotein
  • Colon cancer
  • FOLFIRI
  • FOLFOX
  • Hepatocellular carcinoma
  • Hepatoid adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Hepatoid adenocarcinoma of the colon : What should we target? / Cappetta, Alessandro; Bergamo, Francesca; Mescoli, Claudia; Lonardi, Sara; Rugge, Massimo; Zagonel, Vittorina.

In: Pathology and Oncology Research, Vol. 18, No. 1, 01.2012, p. 93-96.

Research output: Contribution to journalArticle

Cappetta, Alessandro ; Bergamo, Francesca ; Mescoli, Claudia ; Lonardi, Sara ; Rugge, Massimo ; Zagonel, Vittorina. / Hepatoid adenocarcinoma of the colon : What should we target?. In: Pathology and Oncology Research. 2012 ; Vol. 18, No. 1. pp. 93-96.
@article{36f18a49f727411cb80f8aa483a9c761,
title = "Hepatoid adenocarcinoma of the colon: What should we target?",
abstract = "Hepatoid adenocarcinoma is a rare extra hepatic neoplasm that displays morphological and phenotypic features similar to those of hepatocellular carcinoma. We report a case of a 75-year-old woman, presenting with abdominal pain and complaints of weakness and lost of appetite, who was found to have a mass on her right colon. She underwent right hemicolectomy for a pT3N2M0, stage IIIC colon cancer. The tumor phenotype and immunophenotype, as documented by alpha-fetoprotein immunoreaction positivity, were consistent with adenocarcinoma of hepatoid origin. The patient received FOLFOX-4 regimen as adjuvant treatment, relapsed after six cycles, then was switched to FOLFIRI regimen plus Bevacizumab and progressed after only four cycles. She died 1 month later, eight months after the diagnosis. The lack of any clinical benefit despite an aggressive and multimodal therapeutic strategy, raises a question about what should be targeted when we face this rare disease associated with a very poor prognosis.",
keywords = "Alpha-fetoprotein, Colon cancer, FOLFIRI, FOLFOX, Hepatocellular carcinoma, Hepatoid adenocarcinoma",
author = "Alessandro Cappetta and Francesca Bergamo and Claudia Mescoli and Sara Lonardi and Massimo Rugge and Vittorina Zagonel",
year = "2012",
month = "1",
doi = "10.1007/s12253-011-9424-5",
language = "English",
volume = "18",
pages = "93--96",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Hepatoid adenocarcinoma of the colon

T2 - What should we target?

AU - Cappetta, Alessandro

AU - Bergamo, Francesca

AU - Mescoli, Claudia

AU - Lonardi, Sara

AU - Rugge, Massimo

AU - Zagonel, Vittorina

PY - 2012/1

Y1 - 2012/1

N2 - Hepatoid adenocarcinoma is a rare extra hepatic neoplasm that displays morphological and phenotypic features similar to those of hepatocellular carcinoma. We report a case of a 75-year-old woman, presenting with abdominal pain and complaints of weakness and lost of appetite, who was found to have a mass on her right colon. She underwent right hemicolectomy for a pT3N2M0, stage IIIC colon cancer. The tumor phenotype and immunophenotype, as documented by alpha-fetoprotein immunoreaction positivity, were consistent with adenocarcinoma of hepatoid origin. The patient received FOLFOX-4 regimen as adjuvant treatment, relapsed after six cycles, then was switched to FOLFIRI regimen plus Bevacizumab and progressed after only four cycles. She died 1 month later, eight months after the diagnosis. The lack of any clinical benefit despite an aggressive and multimodal therapeutic strategy, raises a question about what should be targeted when we face this rare disease associated with a very poor prognosis.

AB - Hepatoid adenocarcinoma is a rare extra hepatic neoplasm that displays morphological and phenotypic features similar to those of hepatocellular carcinoma. We report a case of a 75-year-old woman, presenting with abdominal pain and complaints of weakness and lost of appetite, who was found to have a mass on her right colon. She underwent right hemicolectomy for a pT3N2M0, stage IIIC colon cancer. The tumor phenotype and immunophenotype, as documented by alpha-fetoprotein immunoreaction positivity, were consistent with adenocarcinoma of hepatoid origin. The patient received FOLFOX-4 regimen as adjuvant treatment, relapsed after six cycles, then was switched to FOLFIRI regimen plus Bevacizumab and progressed after only four cycles. She died 1 month later, eight months after the diagnosis. The lack of any clinical benefit despite an aggressive and multimodal therapeutic strategy, raises a question about what should be targeted when we face this rare disease associated with a very poor prognosis.

KW - Alpha-fetoprotein

KW - Colon cancer

KW - FOLFIRI

KW - FOLFOX

KW - Hepatocellular carcinoma

KW - Hepatoid adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84855295737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855295737&partnerID=8YFLogxK

U2 - 10.1007/s12253-011-9424-5

DO - 10.1007/s12253-011-9424-5

M3 - Article

C2 - 21667305

AN - SCOPUS:84855295737

VL - 18

SP - 93

EP - 96

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -